Mabwell and Aditum Bio Launch Kalexo Bio to Develop siRNA Cardiovascular Therapies

Mabwell (Shanghai) Bioscience Co., Ltd. and Aditum Bio have announced the formation of a new biotech company, Kalexo Bio, focused on developing RNA-based therapies for cardiovascular disease. The launch comes alongside an exclusive global licensing agreement to advance 2MW7141, a novel dual-target siRNA candidate designed for lipid management in patients with dyslipidemia and to prevent atherosclerotic cardiovascular disease (ASCVD) events.

2MW7141 represents a next-generation therapeutic approach targeting multiple genetic pathways involved in lipid regulation and cardiovascular risk. The compound will be the lead asset for Kalexo Bio, which aims to initiate clinical development in the near future.

Aditum Bio, known for its incubator-style model for drug development, will provide full funding for Kalexo Bio and support its operations with a team of experienced development professionals. The collaboration reflects both companies’ commitment to accelerating therapies in areas with high unmet medical need.

“Kalexo Bio embodies our shared vision of advancing transformative RNA-based treatments for serious cardiovascular conditions,” said representatives from Mabwell and Aditum in a joint statement.

The partnership marks a strategic move for Mabwell to expand its global footprint and for Aditum Bio to continue leveraging its unique company-building platform to bring innovative therapies to patients faster.